Skip to main content

Table 3 Predictive role of baseline PHD1, PHD2 and PHD3 positivity for disease response in overall cases

From: The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen

 

No response

Partial Response

Complete Response

P value

PHD1-positive

13/38 (34.2%)

28/105 (26.7%)

6/32 (18.7%)

0.15

PHD2-positive

18/35 (51.4%)

45/97 (46.4%)

21/30 (70.0%)

0.17

PHD3-positive

19/38 (50.0%)

39/105 (37.1%)

11/33 (33.3%)

0.14

  1. One patient was not assessable for disease response due to treatment refusal after one cycle.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us